Condition: Vascular Ehlers-Danlos Syndrome · Sponsor: Acer Therapeutics Inc.
This is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as COL3A1-positive vEDS using a decentralized clinical trial design.
This description comes directly from the study's public registry record.
Sheila Woodhouse, MD; Ph.D. · 984-377-3737 · sheila.woodhouse@science37.com
Jonathan Cotliar, MD; Ph.D. · 984-377-3737 · jonathan@science37.com
Always discuss trial participation with your own doctor first.
| Science 37 | Culver City, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05432466